89
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Proteolysis-Targeting Chimeras Targeting Epigenetic Modulators: A Promising Strategy for Oral Cancer Therapy

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1233-1236 | Received 22 Aug 2023, Accepted 08 Nov 2023, Published online: 22 Nov 2023

References

  • Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin.71(3), 209–249 (2021).
  • Mumtaz M , BijnsdorpIV, BöttgerFet al. Secreted protein markers in oral squamous cell carcinoma (OSCC). Clin. Proteomics19(1), 4 (2022).
  • Swarup N , HongKO, ChawlaKet al. Effect of PAIP1 on the metastatic potential and prognostic significance in oral squamous cell carcinoma. Int. J. Oral Sci.14(1), 9 (2022).
  • Li X , SongY. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J. Hematol. Oncol.13(1), 50 (2020).
  • Wang C , ZhangY, ShiLet al. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents. J. Enzyme Inhib. Med. Chem.37(1), 1437–1453 (2022).
  • He Y , KhanS, HuoZet al. Proteolysis targeting chimaeras (PROTACs) are emerging therapeutics for hematologic malignancies. J. Hematol. Oncol.13(1), 103 (2020).
  • Usman S , JamalA, TehMT, WaseemA. Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance. Front. Oral Health.1, 603160 (2021).
  • Li X , PuW, ZhengQ, AiM, ChenS, PengY. Proteolysis-targeting chimaeras (PROTACs) in cancer therapy. Mol. Cancer.21(1), 99 (2022).
  • Chen WC , ChenMF, LinPY. Significance of DNMT3b in oral cancer. PLOS ONE9(3), e89956 (2014).
  • Hsu JH , RasmussonT, RobinsonJet al. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. Cell Chem. Biol.27(1), 41–46.e17 (2020).
  • Yamamoto T , HirosueA, NakamotoMet al. BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene. Br. J. Cancer123(4), 580–590 (2020).
  • Qin C , HuY, ZhouBet al. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J. Med. Chem.61(15), 6685–6704 (2018).
  • Gechijian LN , BuckleyDL, LawlorMAet al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat. Chem. Biol.14(4), 405–412 (2018).
  • Cho YA , HongJS, ChoeEJet al. The role of p300 in the tumor progression of oral squamous cell carcinoma. J. Oral Pathol. Med.44(3), 185–192 (2015).
  • Sajnani AK , ShahSG, RashidM, NatuA, GeraPB, GuptaS. In-Silico Analysis of Chromatin Modifiers and Profiling of Histone Deacetylases (HDAC’s) in Human Oral Cancer. Chonnam. Med. J.57(3), 176–184 (2021).
  • Carafa V , AltucciL, NebbiosoA. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Front. Pharmacol.10, 38 (2019).
  • Schiedel M , HerpD, HammelmannSet al. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). J. Med. Chem.61(2), 482–491 (2018).
  • Chen L , WanX, ShanX, ZhaW, FanR. Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy. Mol. Diagn. Ther.26(3), 283–291 (2022).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.